MUS81 Loss

CI-VAR-00002500Explore in graph →CIViC 4702

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Ovarian Neoplasm1
NBN Loss OR ATM Loss OR MUS81 Loss OR RAD51B Loss OR BRCA2 Loss	Olaparib	Predictive	D	Supports Sensitivity Response	2	submitted	EID11728 To test for genes associated with PARPi response, a literature review of 79 publications was done, followed by CRISPR-Cas9 cell competition assays in combination with olaparib treatment in six EOC cel… (full text at CIViC) PMID 36307400 · Coelho et al., 2022 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.